arrow
P

Peter Palese

Icahn School of Medicine at Mount Sinai
H指数:141
被引数:6.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunodominance hierarchy of influenza A haemagglutinin antigenic sites: an observational cohort study across distinct exposure histories

甲型流感血凝素抗原位点的免疫优势层级:一项跨越不同暴露史的观察性队列研究

2026-08-060
OA
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults

先前接种过疫苗的成人鼻腔内接种NDV-HXP-S的I期临床试验

Vaccine
IF3.5
2026-06-010
PRE
Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates

基于AS03佐剂嵌合HA的流感疫苗在非人灵长类动物的骨髓和淋巴结中诱导产生长寿的杆状特异性浆细胞

2025-10-150
OAAI
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil

重组新城病病毒灭活疫苗表达SARS-CoV-2刺突蛋白的安全性及免疫原性:巴西随机疫苗对照的I期ADAPTCOV试验结果

VACCINE
IF3.5
2025-04-010
PRE
A Surrogate Enzyme-Linked Immunosorbent Assay to Select High-Titer Human Convalescent Plasma for Treating Immunocompromised Patients Infected With Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern
2025-01-030
PRE
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach

基于镶嵌血凝素方法的通用乙型流感灭活疫苗的临床前评估

2024-11-170
OAAI
Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity
2024-09-160
OAAI
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals
2024-05-301
OAAI
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

墨西哥基于NDV的新型冠状病毒肺炎疫苗I期试验的临时安全性和免疫原性结果

2023-05-1023
OAAI
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults
2023-04-1931
OA